866-997-4948(US-Canada Toll Free)

Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020

Published By :

GlobalData

Published Date : Nov 2010

Category :

Cancer

No. of Pages : 195 Pages


GlobalData, the industry analysis specialist, has released its new report, Colorectal Cancer Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020. The report is an essential source of information and analysis on the colorectal cancer therapeutics market in emerging countries, Brazil, China, India and Russia (BRIC). The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the colorectal cancer therapeutics market in Brazil, Russia, India and China. It analyses the treatment usage patterns in colorectal cancer therapeutics marketing BRIC countries. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the BRIC colorectal cancer therapeutics market, highlighting the opportunity for future players. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

Scope

The scope of the report includes: 

  • An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized colorectal cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns data for Brazil, Russia, India and China from 2001 to 2009, forecast for 11 years to 2020. 
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals and LCM activities.
  • Analysis of unmet need in the market and target product profile including opportunity for target product. 
  • Technology trends analytic framework to assess strength of pipeline. 
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.
  • An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements and marketing rights.
  • Analysis of the current and future market competition in the global colorectal cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.
  • Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

Reasons to buy


The report will enhance your decision making capability. It will allow you to:

  • Develop business strategies and perform superior market quantification analysis by 
  • Understanding the trends shaping and driving the BRIC (Brazil, India, Russia and China) colorectal cancer therapeutics market. 
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the BRIC colorectal cancer therapeutics market till 2020.
  • Quantifying patient population in Brazil, Russia, India and China to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products
  • Identifying market entry points based on safety, efficacy, and pricing parameters. 
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition. 
  • Develop and design your in-licensing and out-licensing strategies by 
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
Table Of Content

1 Table of contents 3
1.1 List of Tables 6
1.2 List of Figures 8

2 Disease Overview 10
2.1 Overview 10
2.2 Epidemiology 12
2.3 Etiology 12
2.4 Symptoms 13
2.4.1 Colon Cancer 13
2.4.2 Rectal Cancer 13
2.5 Diagnosis 14
2.5.1 FOBT 14
2.5.2 Endoscopy 14
2.5.3 Optical Colonoscopy 14
2.5.4 Virtual Colonoscopy 15
2.5.5 Double Contrast Barium Enema (DCBE) 15
2.6 Pathology 15
2.6.1 Grading 15
2.7 Treatment 16
2.7.1 Colon Cancer Treatment by Stage 17
2.7.2 Rectal Cancer Treatment by Stage 19
2.7.3 Chemotherapy Options 21
2.8 Treatment Guidelines 23

3 Market Characterization 25
3.1 BRIC (Brazil, Russia, India and China) 25
3.1.1 Market Size 25
3.1.2 Forecasts 30
3.2 Brazil 35
3.2.1 Market Size 35
3.2.2 Drivers and Restraints 40
3.2.3 Impact on the Market 41
3.2.4 Forecasts 42
3.2.5 Future Impact 47
3.3 India 48
3.3.1 Market Size 48
3.3.2 Drivers and Restraints 53
3.3.3 Impact on the Market 54
3.3.4 Forecasts 55
3.3.5 Future Impact 60
3.4 China 61
3.4.1 Market Size 61
3.4.2 Drivers and Restraints 66
3.4.3 Impact on the Market 67
3.4.4 Forecasts 68
3.4.5 Future Impact 73
3.5 Russia 74
3.5.1 Market Size 74
3.5.2 Drivers and Restraints 79
3.5.3 Impact on the Market 80
3.5.4 Forecasts 81
3.5.5 Future Impact 86
3.6 Key Takeaway 86

4 Competitor Assessment 87
4.1 Strategic Competitor Assessment 87
4.1.1 Overview 87
4.1.2 Benchmarking 87
4.1.3 Current Competitor Assessment 90
4.2 Product Profiles 91
4.2.1 Avastin (bevacizumab) 92
4.2.2 Erbitux (cetuximab) 95
4.2.3 Xeloda (capecitabine) 98
4.2.4 Vectibix (panitumumab) 103
4.2.5 Eloxatin (oxaliplatin) 108
4.2.6 Camptosar (irinotecan) 111
4.2.7 Fluorouracil (5-FU) 113
4.2.8 Leucovorin (folinic acid) 114
4.3 Key Takeaway 115

5 Pipeline Assessment 116
5.1 Overview 116
5.2 Pipeline Analysis by Phase of Development 117
5.3 Pipeline by Mechanism of Action 118
5.4 Strategic Pipeline Assessment 119
5.4.1 Technology Trends Analytical Framework 119
5.5 Trends in Colorectal Cancer Pipeline 120
5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer 120
5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline 120
5.5.3 Failure of key Molecules in Phase II and Phase III Development 120
5.6 Partners in Development 121
5.6.1 Licensing Agreements by Phase of Development 121
5.6.2 Licensing Agreements by Geography 123
5.6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology 124
5.7 Most Promising Drugs Profiles 126
5.7.1 Aflibercept 126
5.7.2 Brivanib 127
5.7.3 OncoVAX 128
5.7.4 TroVax 130
5.7.5 KRX-0401 (Perifosine) 131
5.8 Colorectal Cancer Pipeline Preclinical Phase 133
5.9 Colorectal Cancer Pipeline Phase I 133
5.10 Colorectal Cancer Pipeline Phase II 135
5.11 Colorectal Cancer Pipeline Phase III 142
5.12 Key Takeaway 145

6 Unmet Need and Target Product Profile 146
6.1 Unmet Need 147
6.2 Opportunity for Target Product 148
6.3 Target Product Profile 150
6.3.1 Ideal Characteristics 150
6.3.2 Target Product Description 150
6.4 Key Takeaway 151

7 Strategic Assessment 152
7.1 Key Events Impacting the Future Market 152
7.2 Market Impact Analysis 152
7.3 Future Market Scenario 152
7.4 Key Takeaway 154

8 Company Profiles 155
8.1 F. Hoffmann La Roche 155
8.1.1 Business Description 155
8.1.2 Financial Overview 155
8.1.3 SWOT Analysis 155
8.2 Bristol-Myers Squibb 157
8.2.1 Business Description 157
8.2.2 Financial Overview 157
8.2.3 SWOT Analysis 157
8.3 Sanofi-Aventis 159
8.3.1 Business Description 159
8.3.2 Financial Overview 159
8.3.3 SWOT Analysis 159
8.4 Debiopharm Group 160
8.4.1 Business Description 160
8.5 Merck KGaA 160
8.5.1 Business Description 160
8.5.2 Financial Overview 161
8.5.3 SWOT Analysis 161
8.6 Regeneron 162
8.6.1 Business Description 162
8.6.2 Financial Overview 163
8.6.3 SWOT Analysis 163
8.7 Vaccinogen BD 164
8.7.1 Overview 164
8.7.2 SWOT Analysis 165
8.8 Oxford BioMedica 165
8.8.1 Business Description 165
8.8.2 Financial Overview 166
8.8.3 SWOT Analysis 167
8.9 Auron Healthcare GmbH 168
8.9.1 Company Overview 168
8.10 AEterna Zentaris 168
8.10.1 Business Description 168
8.10.2 Financial Overview 168
8.10.3 SWOT Analysis 169
8.11 Keryx 171
8.11.1 Business Description 171
8.11.2 Financial Overview 172
8.11.3 SWOT Anlaysis 172
8.12 Abbott Laboratories 175
8.12.1 Business Description 175
8.12.2 Financial Performance 175
8.12.3 SWOT Analysis 175
8.13 Pfizer 177
8.13.1 Business Description 177
8.13.2 Financial Overview 178
8.13.3 SWOT Analysis 178
8.14 Light Sciences Oncology, Inc 179
8.14.1 Business Description 179
8.14.2 Financial Overview 179
8.14.3 SWOT Analysis 180

9 Deals Analysis 182
9.1 Key Highlights 182
9.2 Key Deals Analysis 183
9.2.1 Eli Lilly Acquires ImClone 183
9.2.2 Astellas Pharma Acquires OSI Pharmaceuticals 183
9.2.3 Takeda Acquires IDM Pharma 183
9.2.4 Alchemia Acquires Meditech 183
9.2.5 Sanofi-Aventis Acquired Additional 15% Stake in Regeneron 183
9.2.6 BBM Holdings to Acquire YM Biosciences 183
9.2.7 Pfizer Acquires Assets of Campto from Sanofi-Aventis 183
9.2.8 Peptech Acquires cancer Antibodies from Scancell 184
9.2.9 Quest Pharma Tech Inc. Acquired Late Stage Immunotherapy Product Pipeline of Paladin Labs 184
9.2.10 Spectrum Pharmaceuticals Inc Acquired Oncology Drug Assets from Targent Inc 184
9.3 Deals Analysis by Geography 185
9.4 Deals Analysis by Deal Size 186

10 Appendix 187
10.1 Market Definitions 187
10.2 Abbreviations 187
10.3 Research Methodology 189
10.3.1 Coverage 189
10.3.2 Secondary Research 189
10.3.3 Forecasting 190
10.3.4 Primary Research 193
10.3.5 Expert Panel validation 193
10.3.6 Contact Us 193
10.4 Disclaimer 193
10.5 Sources 194

List of Table


Table 1: Colorectal Cancer Therapeutics Market, Global, Staging of Colorectal Cancer, 2010 11
Table 2: Colorectal Cancer Therapeutics Market, Global, WHO Classification of Colorectal Carcinomas, 2010 16
Table 3: Colorectal Cancer Therapeutics Market, BRIC, Sales Value ($bn), 20012009 25
Table 4: Colorectal Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 20012009 26
Table 5: Colorectal Cancer Therapeutics Market, BRIC, Patient Volume, 20012009 27
Table 6: Colorectal Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 20012009 28
Table 7: Colorectal Cancer Therapeutics Market, BRIC, Sales Value ($bn), 20092020 30
Table 8: Colorectal Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 20092020 31
Table 9: Colorectal Cancer Therapeutics Market, BRIC, Patient Volume (absolute), 20092020 32
Table 10: Colorectal Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 20092020 33
Table 11: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 20012009 35
Table 12: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 20012009 36
Table 13: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 20012009 37
Table 14: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 20012009 38
Table 15: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 20092020 42
Table 16: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 20092020 43
Table 17: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 20092020 44
Table 18: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 20092020 45
Table 19: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 20012009 48
Table 20: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 20012009 49
Table 21: Colorectal Cancer Therapeutics Market, India, Patient Volume, 20012009 50
Table 22: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 20012009 51
Table 23: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 20092020 55
Table 24: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 20092020 56
Table 25: Colorectal Cancer Therapeutics Market, India, Patient Volume, 20092020 57
Table 26: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 20092020 58
Table 27: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 20012009 61
Table 28: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 20012009 62
Table 29: Colorectal Cancer Therapeutics Market, China, Patient Volume, 20012009 63
Table 30: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 20012009 64
Table 31: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 20092020 68
Table 32: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 20092020 69
Table 33: Colorectal Cancer Therapeutics Market, China, Patient Volume, 20092020 70
Table 34: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 20092020 71
Table 35: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 20012009 74
Table 36: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 20012009 75
Table 37: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 20012009 76
Table 38: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 20012009 77
Table 39: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 20092020 81
Table 40: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 20092020 82
Table 41: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 20092020 83
Table 42: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 20092020 84
Table 43: Colorectal Cancer, Global, Safety Profile of Standard Treatment, 2010 89
Table 44: Colorectal Cancer Therapeutics Market, Global, Benchmarking Major Marketed Products, 2010 91
Table 45: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010 93
Table 46: Colorectal Cancer Therapeutics Market, Global, Erbitux, Incidence of Adverse Effects, 2010 96
Table 47: Colorectal Cancer Therapeutics Market, Global, Xeloda, Adverse Effects Incidence, 2010 100
Table 48: Colorectal Cancer Therapeutics Market, Global, Vectibix, PRECEPT Interim Results, 2010 104
Table 49: Colorectal Cancer Therapeutics Market, Global, Vectibix, Incidence of Adverse Events, 2010 105
Table 50: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010 109
Table 51: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Incidence of Adverse Events, 2010 109
Table 52: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010 125
Table 53: Colorectal Cancer Therapeutics Market, Global, Preclinical Phase Pipeline, July 2010 133
Table 54: Colorectal Cancer, Global, Phase I Pipeline, July 2010 133
Table 55: Colorectal Cancer, Global, Phase II Pipeline, July 2010 135
Table 56: Colorectal Cancer, Global, Phase III Pipeline, July 2010 142
Table 57: Colorectal Cancer Therapeutics Market, Global, Commonly Prescribed Treatment Options, 2010 147
Table 58: Colorectal Cancer Therapeutics Market, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010 150
Table 59: Colorectal Cancer Therapeutics Market, Global, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010 150

List of Chart


Figure 1: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010 23
Figure 2: Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010 24
Figure 3: Colorectal Cancer Therapeutics Market, BRIC, Sales Value ($bn), 20012009 25
Figure 4: Colorectal Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 20012009 26
Figure 5: Colorectal Cancer Therapeutics Market, BRIC, Patient Volume, 20012009 27
Figure 6: Colorectal Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 20012009 28
Figure 7: Colorectal Cancer Therapeutics Market, BRIC, Sales Value ($bn), 20092020 30
Figure 8: Colorectal Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 20092020 31
Figure 9: Colorectal Cancer Therapeutics Market, BRIC, Patient Volume (absolute), 20092020 32
Figure 10: Colorectal Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 20092020 33
Figure 11: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 20012009 35
Figure 12: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 20012009 36
Figure 13: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 20012009 37
Figure 14: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 20012009 38
Figure 15: Colorectal Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2009 40
Figure 16: Colorectal Cancer Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2010 41
Figure 17: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 20092020 42
Figure 18: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 20092020 43
Figure 19: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 20092020 44
Figure 20: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 20092020 45
Figure 21: Colorectal Cancer Therapeutics Market, Brazil, Future Market Drivers and Restraints, 20092020 47
Figure 22: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 20012009 48
Figure 23: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 20012009 49
Figure 24: Colorectal Cancer Therapeutics Market, India, Patient Volume, 20012009 50
Figure 25: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 20012009 51
Figure 26: Colorectal Cancer Therapeutics Market, India, Market Drivers and Restraints, 2009 53
Figure 27: Colorectal Cancer Therapeutics Market, India, The Impact of Historical Events on the Market, 2010 54
Figure 28: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 20092020 55
Figure 29: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 20092020 56
Figure 30: Colorectal Cancer Therapeutics Market, India, Patient Volume, 20092020 57
Figure 31: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 20092020 58
Figure 32: Colorectal Cancer Therapeutics Market, India, Future Market Drivers and Restraints, 20092020 60
Figure 33: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 20012009 61
Figure 34: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 20012009 62
Figure 35: Colorectal Cancer Therapeutics Market, China, Patient Volume, 20012009 63
Figure 36: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 20012009 64
Figure 37: Colorectal Cancer Therapeutics Market, China, Market Drivers and Restraints, 2010 66
Figure 38: Colorectal Cancer Therapeutics Market, China, The Impact of Historical Events on the Market, 2010 67
Figure 39: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 20092020 68
Figure 40: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 20092020 69
Figure 41: Colorectal Cancer Therapeutics Market, China, Patient Volume, 20092020 70
Figure 42: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 20092020 71
Figure 43: Colorectal Cancer Therapeutics Market, China, Future Market Drivers and Restraints, 20092020 73
Figure 44: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 20012009 74
Figure 45: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 20012009 75
Figure 46: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 20012009 76
Figure 47: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 20012009 77
Figure 48: Colorectal Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2009 79
Figure 49: Colorectal Cancer Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2010 80
Figure 50: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 20092020 81
Figure 51: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 20092020 82
Figure 52: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 20092020 83
Figure 53: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 20092020 84
Figure 54: Colorectal Cancer Therapeutics Market, Russia, Future Market Drivers and Restraints, 20092020 86
Figure 55: Colorectal Cancer Therapeutics Market, Global, Clinical Endpoints for Benchmarking, 2010 88
Figure 56: Colorectal Cancer Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2010 90
Figure 57: Colorectal Cancer Therapeutics Market, Global, Avastin, Life Cycle Management Activities, 20042010 94
Figure 58: Colorectal Cancer Therapeutics Market, Global, Erbitux, Life Cycle Management Activities, 20042010 98
Figure 59: Colorectal Cancer Therapeutics Market, Global, Xeloda, Chemical Structure, 2010 99
Figure 60: Colorectal Cancer Therapeutics Market, Global, Xeloda, Life Cycle Management Activities, 2010 102
Figure 61: Colorectal Cancer Therapeutics Market, Global, Vectibix, Life Cycle Management Activities, 2010 107
Figure 62: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Chemical Structure, 2010 108
Figure 63: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Life Cycle Management Activities, 2010 110
Figure 64: Colorectal Cancer Therapeutics Market, Global, Camptosar, Chemical Structure 111
Figure 65: Colorectal Cancer Therapeutics Market, Global, Camptosar, Life Cycle Management Activities, 2010 112
Figure 66: Colorectal Cancer Therapeutics Market, Global, Fluorouracil, Chemical Structure 113
Figure 67: Colorectal Cancer Therapeutics Market, Global, Leucovorin, Chemical Structure 114
Figure 68: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Therapy (%), 2010 116
Figure 69: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2010 117
Figure 70: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010 118
Figure 71: Colorectal Cancer Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 119
Figure 72: Colorectal Cancer Therapeutics Market, Global, Technology Trends Description of Pipeline Drugs, 2010 120
Figure 73: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2004-2010 121
Figure 74: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Geography (%), 2010 123
Figure 75: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Screening/Diagnostic Technology (%), 2010 124
Figure 76: Colorectal Cancer Therapeutics Market, Global, Brivanib Chemical Structure, 2010 127
Figure 77: Colorectal Cancer Therapeutics Market, Global, Perifosine Chemical Structure, 2010 131
Figure 78: Colorectal Cancer Therapeutics Market, Global, Median Overall Survival for Metastatic Colorectal Cancer Patients (months), 2010 146
Figure 79: Colorectal Cancer Therapeutics Market, Global, Opportunity and Unmet Need, 2010 148
Figure 80: Colorectal Cancer Therapeutics Market, Unmet Need by Geography, 2010 149
Figure 81: Colorectal Cancer, Global, Key Events Impacting the Future Market 152
Figure 82: Colorectal Cancer Therapeutics Market, Global, Implications for Future Market Competition, 2010 153
Figure 83: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2010 182
Figure 84: Colorectal Cancer Therapeutics Market, Global, Merger and Acqusition Deals by Geography (%), 2010 185
Figure 85: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size (%), 2010 186
Figure 86: GlobalData Market Forecasting Model 192

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *